Aspirin, Ibuprofen, and the Risk for Colorectal Cancer in Lynch Syndrome

被引:56
|
作者
Ouakrim, Driss Ait [1 ]
Dashti, Seyedeh Ghazaleh [1 ]
Chau, Rowena [1 ]
Buchanan, Daniel D. [1 ,2 ]
Clendenning, Mark [2 ]
Rosty, Christophe [2 ,3 ]
Winship, Ingrid M. [4 ,5 ]
Young, Joanne P. [6 ,7 ,8 ]
Giles, Graham G. [1 ,9 ]
Leggett, Barbara [10 ]
Macrae, Finlay A. [4 ,5 ,11 ]
Ahnen, Dennis J. [12 ]
Casey, Graham [13 ,14 ]
Gallinger, Steven [15 ]
Haile, Robert W. [16 ]
Le Marchand, Loic [17 ]
Thibodeau, Stephen N. [18 ]
Lindor, Noralane M. [19 ]
Newcomb, Polly A. [20 ,21 ]
Potter, John D. [20 ,21 ,22 ]
Baron, John A. [23 ]
Hopper, John L. [1 ,24 ,25 ]
Jenkins, Mark A. [1 ]
Win, Aung Ko [1 ]
机构
[1] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Parkville, Vic 3010, Australia
[2] Univ Melbourne, Dept Pathol, Genet Epidemiol Lab, Oncogenom Grp, Parkville, Vic 3052, Australia
[3] Univ Queensland, Sch Med, Herston, Qld, Australia
[4] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia
[5] Royal Melbourne Hosp, Genet Med & Family Canc Clin, Parkville, Vic 3050, Australia
[6] Queen Elizabeth Hosp, Dept Haematol & Oncol, Woodville, SA 5011, Australia
[7] Basil Hetzel Inst Translat Res, SAHMRI Colorectal Node, Woodville, SA, Australia
[8] Univ Adelaide, Sch Med, Adelaide, SA 5005, Australia
[9] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia
[10] Royal Brisbane Hosp, QIMR Berghofer Med Res Inst, Herston, Qld, Australia
[11] Royal Melbourne Hosp, Colorectal Med & Genet, Parkville, Vic, Australia
[12] Univ Colorado, Sch Med, Dept Med, Denver, CO USA
[13] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA
[14] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[15] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada
[16] Stanford Univ, Stanford Canc Inst, Div Oncol, Dept Med, Stanford, CA 94305 USA
[17] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA
[18] Mayo Clin, Dept Lab Med & Pathol, Mol Genet Lab, Rochester, MN USA
[19] Mayo Clin, Dept Hlth Sci Res, Scottsdale, AZ USA
[20] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA
[21] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA
[22] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand
[23] Univ N Carolina, Dept Med, Chapel Hill, NC USA
[24] Seoul Natl Univ, Dept Epidemiol, Seoul, South Korea
[25] Seoul Natl Univ, Sch Publ Hlth, Inst Hlth & Environm, Seoul, South Korea
来源
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
REPAIR GENE MUTATION; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RESISTANT STARCH; FAMILY REGISTRY; RECTAL ADENOMAS; BREAST-CANCER; COLON-CANCER; CARRIERS; PREVENTION; RECOMMENDATIONS;
D O I
10.1093/jnci/djv170
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Inheritance of a germline mutation in one of the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2 causes a high risk of colorectal and other cancers (Lynch Syndrome). Use of aspirin has been shown to be associated with a reduced risk of colorectal cancer for the general population as well as for MMR gene mutation carriers. The aim of this study was to determine whether use of aspirin and ibuprofen in a nontrial setting is associated with the risk of colorectal cancer risk for MMR gene mutation carriers. Methods: We included 1858 participants in the Colon Cancer Family Registry who had been found to have a pathogenic germline mutation in a MMR gene (carriers). We used weighted Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. Results: A total of 714 carriers (38%) were diagnosed with colorectal cancer at a mean age of 42.4 (standard deviation 10.6) years. A reduced risk of colorectal cancer was associated with aspirin use (for 1 month to 4.9 years: HR = 0.49, 95% CI = 0.27 to 0.90, P = .02; for = 5 years: HR = 0.25, 95% CI = 0.10 to 0.62, P = .003) and ibuprofen use (for 1 month to 4.9 years: HR = 0.38, 95% CI = 0.18 to 0.79, P = .009; for >= 5 years: HR = 0.26, 95% CI = 0.10 to 0.69, P = .007), compared with less than one month of use. Conclusion: Our results provide additional evidence that, for MMR gene mutation carriers, use of aspirin and ibuprofen might be effective in reducing their high risk of colorectal cancer.
引用
收藏
页数:11
相关论文
共 50 条
  • [11] Aspirin prevents cancer in Lynch syndrome
    Burn, John
    Gerdes, A-M
    Mathers, J.
    Mecklin, J-P
    Macrae, F.
    Moeslein, G.
    Bisgaard, M-L
    Ramesar, R.
    Eccles, D.
    Maher, E. R.
    Evans, G.
    Morrison, P.
    Bishop, D. T.
    JOURNAL OF MEDICAL GENETICS, 2009, 46 : S27 - S27
  • [12] Assessment of a Polygenic Risk Score for Colorectal Cancer to Predict Risk of Lynch Syndrome Colorectal Cancer
    Jenkins, Mark A.
    Buchanan, Daniel D.
    Lai, John
    Makalic, Enes
    Dite, Gillian S.
    Win, Aung K.
    Clendenning, Mark
    Winship, Ingrid M.
    Hayes, Richard B.
    Huyghe, Jeroen R.
    Peters, Ulrike
    Gallinger, Steven
    Le Marchand, Loic
    Figueiredo, Jane C.
    Pai, Rish K.
    Newcomb, Polly A.
    Church, James M.
    Casey, Graham
    Hopper, John L.
    JNCI CANCER SPECTRUM, 2021, 5 (02)
  • [13] AN ASPIRIN A DAY? THE (STILL) SECRET WEAPON AGAINST COLORECTAL CANCER IN LYNCH SYNDROME
    Tuckey, Rebecca
    Lyng, Shane
    Moore, Alison
    Arnold, Julie L.
    Ben Griffiths
    Vijay, Varnika
    Wensley, Joshua
    Tan, Olivia
    Atkinson, Nathan
    Wakeman, Christopher
    Parry, Susan
    Chalmers-Watson, Teresa
    GASTROENTEROLOGY, 2024, 166 (05) : S1084 - S1084
  • [14] Lynch Syndrome: Immune Microenvironment as a Risk Factor for Colorectal Cancer
    不详
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (07): : 1073 - +
  • [15] Exploring clinicians' attitudes about using aspirin for risk reduction in people with Lynch Syndrome with no personal diagnosis of colorectal cancer
    Chen, Yanni
    Peate, Michelle
    Kaur, Rajneesh
    Meiser, Bettina
    Wong, Tim
    Kirk, Judy
    Ward, Robyn L.
    Goodwin, Annabel
    Macrae, Finlay
    Hiller, Janet
    Trainer, Alison H.
    Mitchell, Gillian
    FAMILIAL CANCER, 2017, 16 (01) : 99 - 109
  • [16] Exploring clinicians’ attitudes about using aspirin for risk reduction in people with Lynch Syndrome with no personal diagnosis of colorectal cancer
    Yanni Chen
    Michelle Peate
    Rajneesh Kaur
    Bettina Meiser
    Tim Wong
    Judy Kirk
    Robyn L. Ward
    Annabel Goodwin
    Finlay Macrae
    Janet Hiller
    Alison H. Trainer
    Gillian Mitchell
    Familial Cancer, 2017, 16 : 99 - 109
  • [17] Ability of a polygenic risk score to refine colorectal cancer risk in Lynch syndrome
    Duenas, Nuria
    Klinkhammer, Hannah
    Bonifaci, Nuria
    Spier, Isabel
    Mayr, Andreas
    Hassanin, Emadeldin
    Diez-Villanueva, Anna
    Moreno, Victor
    Pineda, Marta
    Maj, Carlo
    Capella, Gabriel
    Aretz, Stefan
    Brunet, Joan
    JOURNAL OF MEDICAL GENETICS, 2023, 60 (11) : 1044 - 1051
  • [18] Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome
    Burn, John
    Bishop, D. Timothy
    Mecklin, Jukka-Pekka
    Macrae, Finlay
    Moeslein, Gabriela
    Olschwang, Sylviane
    Bisgaard, Marie-Luise
    Ramesar, Raj
    Eccles, Diana
    Maher, Eamonn R.
    Bertario, Lucio
    Jarvinen, Heikki J.
    Lindblom, Annika
    Evans, D. Gareth
    Lubinski, Jan
    Morrison, Patrick J.
    Ho, Judy W. C.
    Vasen, Hans F. A.
    Side, Lucy
    Thomas, Huw J. W.
    Scott, Rodney J.
    Dunlop, Malcolm
    Barker, Gail
    Elliott, Faye
    Jass, Jeremy R.
    Fodde, Ricardo
    Lynch, Henry T.
    Mathers, John C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (24): : 2567 - 2578
  • [19] Colorectal cancer screening in Lynch syndrome
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (10): : 667 - 667
  • [20] Lynch syndrome in colorectal cancer patients
    Dolores Giradez, M.
    Castellvi-Bel, Sergi
    Balaguer, Francesc
    Gonzalo, Victoria
    Ocana, Teresa
    Castells, Antoni
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (04) : 573 - 583